Glenmark Pharmaceuticals Ltd
Board Meeting Intimation for The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Year Ended March 31 2023 And To Consider And Recommend Dividend If Any On Equity Shares For The Year Ended March 31 2023.
05:34 PM, 3rd May 2023
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2023 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2023 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2023.Further as per the Code of Conduct for Prevention of Insider Trading and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31 2023 to May 21 2023 (both days inclusive) for the purpose of approval of Audited Financial Results for the Quarter and year ended March 31 2023.